$ASTH

Astrana Health, Inc. Schedules 2026 Second Quarter Financial Results Release and Conference Call

Astrana Health, Inc. (NASDAQ: ASTH) said it will release second-quarter 2026 financial results for the period ended June 30, 2026 after the market close on Aug. 6, 2026. The company will host a conference call that day at 2:30 p.m. PT/5:30 p.m. ET, with a webcast and slide deck on its IR calendar.

Original reporting
Published Jul 14, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 14, 2026, 9:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Astrana Health, Inc. Schedules 2026 Second Quarter Financial Results Release and Conference Call — source image
Decision brief

The 30-second read

$ASTHNeutralMed
01

Why it matters

The main tradable element is the fixed earnings timeline, which can drive options pricing, hedging activity, and pre-earnings positioning into Aug 6.

02

Market read

This sets a concrete catalyst date for ASTH, but provides no new financial or guidance content yet.

03

What to watch

Traders may still need to watch for any pre-announcement leaks, analyst model changes, or changes in healthcare-services sentiment that could amplify the earnings reaction beyond the calendar effect.

Relevance 4/10Novelty 3/10Timing: Ahead of the Aug 6 after-close Q2 2026 earnings release and same-day call.

Background

Astrana Health announced the date and logistics for its Q2 2026 financial results release and conference call.

Company-level read

Ticker impact

$ASTHNeutralHigh confidence
Context

Astrana schedules Q2 2026 results for Aug 6 after the close and a 2:30 p.m. PT conference call the same day.

Expected impact

Likely modest near-term volatility as traders position ahead of the Aug 6 after-close earnings release; direction depends on the forthcoming results.

Evidence & confidence

The article discloses only the timing of the earnings release and call, with no financial figures, guidance, or new operational developments.

Market effects

Limited read-across; scheduling updates typically affect only the issuer’s near-term volatility.

None indicated.

None indicated.

Counterpoint

Because the release date is already a known type of event, the incremental trading edge may be small unless the market is unusually under-positioned for this specific date.

Key entities

  • Astrana Health, Inc.

    NASDAQ-listed physician-centric, technology-enabled healthcare company releasing Q2 2026 results on Aug 6, 2026.

Related articles

$ASTHMed

Astrana Health, Clover Health, Alignment Healthcare, and Novavax Stocks Trade Down, What You Need To Know

Several healthcare stocks fell after bipartisan lawmakers introduced the Protecting Approved Care Act, which aims to reform Medicare Advantage plans. The bill could increase medical loss ratios and administrative burdens for insurers. Astrana Health (ASTH) fell 2.7%, Clover Health (CLOV) 4.8%, Alignment Healthcare (ALHC) 12.6%, and Novavax (NVAX) 3.6%.

$ASTHMedAI 8/10

Astrana Health (ASTH) Q2 2026 Earnings Call Transcript

Astrana Health (ASTH) reported Q2 2026 revenue of $972.5M, up 49% YoY, and adjusted EBITDA of $68.9M, up 43%. Adjusted EPS was $0.80. Six-month free cash flow was $92.9M. The company reaffirmed full-year revenue guidance of $3.8B to $4.1B and raised adjusted EBITDA guidance to $255M to $280M. Net leverage was 2.26.

$ASTHMedAI 8/10

Astrana Health Inc (ASTH) (Q2 2026) Earnings Call Highlights: Record EPS and Raised

Astrana Health Inc (ASTH) reported Q2 2026 results with record EPS and raised guidance, according to management on its earnings call. The company cited a one-time $15 million Q2 revenue reduction tied to CMS adjustments for ACO REACH 2025 billing, with immaterial net EBITDA impact. It also discussed Medicaid membership attrition, commercial cost trends, and wide Q4 2026 EBITDA guidance of $47-$67 million.

$ASTHMed

Astrana Health (NASDAQ:ASTH) Beats Q2 CY2026 Non

Astrana Health (NASDAQ:ASTH) reported Q2 CY2026 revenue of $972.5 million, up 48.5% year on year but below market expectations. Next-quarter revenue guidance was $1.02 billion, about 1.1% under analysts’ estimates. Non-GAAP EPS was $0.80, up 9.6% versus consensus. Shares rose 5.1% to $35.89 after results.

$ASTHHigh

Astrana Health, Inc. (ASTH): Results of Operations and Financial Condition

Astrana Health, Inc. (ASTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Astrana Health, Inc. Reports Second Quarter 2026 Results Company to Host Conference Call on Thursday, August 6, 2026, at 2:30 p.m. PT/5:30 p.m. ET · Reports revenue of $972.5 million, up 49% year-over-year, net income of $18.5 million, up 81% year-over-year, and adju